BTI Stock Analysis: British American Tobacco | NYSE
Tobacco | NYSE, USA | Market Cap: 127.949m USD | 12M Return: 6.2% | US1104481072 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 242M
EPS Trend: -26.3%
Qual. Beats: 0
Rev. Trend: 97.1%
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.6 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
British American Tobacco p.l.c. (BTI) is a UK-headquartered, multinational tobacco and nicotine company founded in 1902 and listed on the NYSE. It operates across the Americas, Europe, Asia-Pacific, the Middle East, Africa, and other regions, distributing its products through retail outlets.
BATs portfolio spans multiple product categories, including vapour products (Vuse), heated tobacco (glo), modern oral nicotine pouches (Velo), traditional oral products such as snus and moist snuff, combustibles (cigarettes), and fine cut/roll-your-own tobacco. The company markets a wide roster of brands, including Newport, Camel, Natural American Spirit, Lucky Strike, Pall Mall, Dunhill, Kent, and Rothmans, alongside Grizzly, Kodiak, and Vogue.
As a large-cap Consumer Staples constituent in the Tobacco sub-industry, BAT is pursuing a multi-category strategy that extends well beyond traditional cigarettes, reflecting the broader tobacco sectors transition toward reduced-risk and next-generation nicotine products as combustible volumes face structural pressure.
- US combustible volume decline offset by premium pricing power
- FDA regulation threatens menthol and flavored product sales
- Vuse and Velo next-generation products drive margin expansion
| Net Income: 6.47b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -2.29 > 1.0 |
| NWC/Revenue: -9.10% < 20% (prev -8.29%; Δ -0.82% < -1%) |
| CFO/TA 0.06 > 3% & CFO 6.03b > Net Income 6.47b |
| Net Debt (33.1b) to EBITDA (12.5b): 2.65 < 3 |
| Current Ratio: 0.84 > 1.5 & < 3 |
| Outstanding Shares: last quarter (2.18b) vs 12m ago -2.51% < -2% |
| Gross Margin: 71.82% > 18% (prev 83.38%; Δ -11.57% > 0.5%) |
| Asset Turnover: 23.66% > 50% (prev 23.22%; Δ 0.44% > 0%) |
| Interest Coverage Ratio: 6.10 > 6 (EBIT TTM 10.2b / Interest Expense TTM 1.66b) |
| A: -0.02 (Total Current Assets 11.9b - Total Current Liabilities 14.3b) / Total Assets 108b |
| B: 0.21 (Retained Earnings 22.8b / Total Assets 108b) |
| C: 0.09 (EBIT TTM 10.2b / Avg Total Assets 109b) |
| D: 0.81 (Book Value of Equity 48.4b / Total Liabilities 59.8b) |
| Altman-Z'' = 2.02 = BBB |
| DSRI: 1.09 (Receivables 3.85b/3.48b, Revenue 25.9b/25.6b) |
| GMI: 1.16 (GM 83.38% / 71.82%) |
| AQI: 1.02 (AQ_t 0.85 / AQ_t-1 0.84) |
| SGI: 1.01 (Revenue 25.9b / 25.6b) |
| TATA: 0.00 (NI 6.47b - CFO 6.03b) / TA 108b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of August 14, 2026, the stock is trading at USD 57.35 with a total of 4,702,901 shares traded. Over the past week, the price has changed by -2.35%, over one month by -2.71%, over three months by -11.02% and over the past year by +6.19%.
Current recommended Stop Loss: 55.40 (which is 3.4% or 1.4 ATR below the current price).
British American Tobacco has received a consensus analysts rating of 3.40. Therefore, it is recommended to hold BTI.
- StrongBuy: 1
- Buy: 2
- Hold: 1
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 70.2 | 22.4% |
Market Cap GBP = 94.7b (128b USD * 0.7401 USD.GBP)
P/E Trailing = 15.1352
P/E Forward = 12.1065
P/S = 4.9639
P/B = 1.9636
P/EG = 1.5724
Revenue TTM = 25.9b GBP
EBIT TTM = 10.2b GBP
EBITDA TTM = 12.5b GBP
Long Term Debt = 31.3b GBP (from longTermDebt, last fiscal year)
Short Term Debt = 4.02b GBP (from shortTermDebt, last quarter)
Debt = 35.6b GBP (from shortLongTermDebtTotal, last quarter) + Leases 529.0m
Net Debt = 33.1b GBP (calculated: Debt 35.6b - CCE 2.53b)
Enterprise Value = 128b GBP (94.7b + Debt 35.6b - CCE 2.53b)
Interest Coverage Ratio = 6.10 (Ebit TTM 10.2b / Interest Expense TTM 1.66b)
EV/FCF = 21.11x (Enterprise Value 128b / FCF TTM 6.05b)
FCF Yield = 4.74% (FCF TTM 6.05b / Enterprise Value 128b)
FCF Margin = 23.39% (FCF TTM 6.05b / Revenue TTM 25.9b)
Net Margin = 25.00% (Net Income TTM 6.47b / Revenue TTM 25.9b)
Gross Margin = 71.82% ((Revenue TTM 25.9b - Cost of Revenue TTM 7.29b) / Revenue TTM)
Gross Margin QoQ = 59.07% (prev 83.42%)
Tobins Q-Ratio = 1.18 (Enterprise Value 128b / Total Assets 108b)
Interest Expense / Debt = 4.68% (Interest Expense 1.66b / Debt 35.6b)
Taxrate = 22.89% (1.92b / 8.37b)
NOPAT = 7.83b (EBIT 10.2b * (1 - 22.89%))
Current Ratio = 0.84 (Total Current Assets 11.9b / Total Current Liabilities 14.3b)
Debt / Equity = 0.74 (Debt 35.6b / totalStockholderEquity, last quarter 48.4b)
Debt / EBITDA = 2.65 (Net Debt 33.1b / EBITDA 12.5b)
Debt / FCF = 5.46 (Net Debt 33.1b / FCF TTM 6.05b)
Total Stockholder Equity = 48.2b (last 4 quarters mean from totalStockholderEquity)
RoA = 5.92% (Net Income 6.47b / Total Assets 108b)
RoE = 13.41% (Net Income TTM 6.47b / Total Stockholder Equity 48.2b)
RoCE = 12.77% (EBIT 10.2b / Capital Employed (Equity 48.2b + L.T.Debt 31.3b))
RoIC = 8.09% (NOPAT 7.83b / Invested Capital 96.8b)
WACC = 4.28% (E(94.7b)/V(130b) * Re(4.54%) + D(35.6b)/V(130b) * Rd(4.68%) * (1-Tc(0.23)))
Discount Rate = 4.54% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -94.85 | Cagr: -1.69%
[DCF] Terminal Value 73.10% ; FCFF base≈7.10b ; Y1≈6.23b ; Y5≈5.03b
[DCF] Fair Price = 22.11 (EV 80.7b - Net Debt 33.1b = Equity 47.7b / Shares 2.16b; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -26.32 | EPS CAGR: -54.01% | SUE: 0.0 | # QB: 0
Revenue Correlation: 97.07 | Revenue CAGR: 34.39% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=4.83 | Chg30d=-0.16% | Revisions=+25% | GrowthEPS=+0.6% | GrowthRev=+2.2%
EPS next Year (2027-12-31): EPS=5.22 | Chg30d=-0.63% | Revisions=+25% | GrowthEPS=+8.0% | GrowthRev=+3.8%
[Analyst] Revisions Ratio: +40% (up=2, down=0)